U.S. markets open in 3 hours 46 minutes
  • S&P Futures

    4,224.00
    +14.00 (+0.33%)
     
  • Dow Futures

    33,387.00
    +127.00 (+0.38%)
     
  • Nasdaq Futures

    13,434.25
    +42.25 (+0.32%)
     
  • Russell 2000 Futures

    1,977.60
    +8.10 (+0.41%)
     
  • Crude Oil

    92.71
    +0.78 (+0.85%)
     
  • Gold

    1,805.20
    -8.50 (-0.47%)
     
  • Silver

    20.47
    -0.27 (-1.31%)
     
  • EUR/USD

    1.0330
    +0.0028 (+0.27%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    20.00
    -1.77 (-8.13%)
     
  • GBP/USD

    1.2213
    -0.0005 (-0.04%)
     
  • USD/JPY

    132.6650
    -0.2080 (-0.16%)
     
  • BTC-USD

    24,522.46
    +1,469.79 (+6.38%)
     
  • CMC Crypto 200

    577.32
    +46.10 (+8.68%)
     
  • FTSE 100

    7,489.23
    -17.88 (-0.24%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Hoth Therapeutics Inc (NASDAQ: HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model.

  • HT-ALZ is therapeutic in development under the 505(b)(2) regulatory pathway for dementia related to Alzheimer's disease.

  • The data support the therapeutic cognitive potential of HT-ALZ after chronic oral dosing.

  • All behavioral tests performed after >5 weeks of treatment showed a significant improvement in the HT-ALZ treated groups compared to the vehicle-treated groups, with similar cognitive and behavioral trends in the HT-ALZ-treated groups compared to the wild-type (non-AD) animals.

  • Related: Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury.

  • Other behavioral assessments performed at earlier treatment periods (less than five weeks) with HT-ALZ did not significantly improve compared to vehicle-treated animals.

  • However, they were trending positively toward improvement, suggesting a time-dependent improvement after initiation of HT-ALZ treatment.

  • These other behavioral assessments are repeated after longer HT-ALZ dosing periods (eg, six weeks).

  • Price Action: HOTH shares are up 28.9% at $0.52 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.